glp-1 weight management program eligibility criteria Nutritional and lifestyle supportive care recommendations for of obesity with - based therapies: An expert consensus statement using a modified Delphi approach BMI for GLP-1: what body

Evelyn Attia, MD, director of the Center for Eating Disorders at NewYork-Presbyterian, says people whove struggled with eating disorders or restrictive dieting should avoid taking GLP-1s

Neither the Wegovy prescribing information nor the Ozempic prescribing information (which uses the same active ingredient, semaglutide, for diabetes management) includes photosensitivity among their documented adverse effects

Beneficiary cost-sharing is capped at $50 per month

in fact, among those who do start using GLP-1s, over 50% stop due to costs, and as many as 36% stop due to side effects

Tirzepatide has been evaluated in large clinical trials for individuals with type 2 diabetes and obesity